Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Active Ankylosing Spondylitis (Phase 3, China)
CTR20181862Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tofacitinib in ankylosing spondylitis (AS), sponsored by Pfizer. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20181862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181862.